| scholarly article | Q13442814 |
| P50 | author | Jeffrey Rubnitz | Q57306302 |
| Monika L Metzger | Q91391717 | ||
| Deepa Bhojwani | Q42324985 | ||
| P2093 | author name string | D Pei | |
| S C Raimondi | |||
| M V Relling | |||
| W E Evans | |||
| H Inaba | |||
| D Campana | |||
| E Coustan-Smith | |||
| W Leung | |||
| C Cheng | |||
| C-H Pui | |||
| J T Sandlund | |||
| R C Ribeiro | |||
| S Jeha | |||
| W P Bowman | |||
| S C Howard | |||
| M Onciu | |||
| S Shurtleff | |||
| P2860 | cites work | Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Mün | Q52999147 |
| Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial | Q58481820 | ||
| Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival | Q61643142 | ||
| L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins | Q71755657 | ||
| TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance | Q73132199 | ||
| Prenatal origin of acute lymphoblastic leukaemia in children | Q73156477 | ||
| Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia | Q74314236 | ||
| Novel cryptic, complex rearrangements involving ETV6-CBFA2 (TEL-AML1) genes identified by fluorescence in situ hybridization in pediatric patients with acute lymphoblastic leukemia | Q74495609 | ||
| Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia | Q74765433 | ||
| TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity | Q75272861 | ||
| Acute lymphoblastic leukemia | Q79891876 | ||
| Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia | Q24319864 | ||
| Treating childhood acute lymphoblastic leukemia without cranial irradiation | Q24644599 | ||
| Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia | Q29614324 | ||
| Chemosensitivity of TEL-AML1 fusion transcript positive acute lymphoblastic leukemia cells | Q30671189 | ||
| Evaluation of survival data and two new rank order statistics arising in its consideration | Q34054360 | ||
| Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group | Q35112206 | ||
| Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase | Q35677647 | ||
| Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study | Q35797316 | ||
| Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. | Q35849716 | ||
| The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells | Q37143354 | ||
| Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia | Q40541692 | ||
| Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study | Q43162649 | ||
| Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells. | Q43238735 | ||
| TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. | Q43505473 | ||
| Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group | Q44280928 | ||
| Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital | Q44976795 | ||
| Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia | Q46638043 | ||
| The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia | Q47335313 | ||
| The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study | Q49279595 | ||
| P433 | issue | 2 | |
| P921 | main subject | leukemia | Q29496 |
| lymphoblastic leukemia | Q18553852 | ||
| P304 | page(s) | 265-270 | |
| P577 | publication date | 2011-08-26 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy | |
| P478 | volume | 26 |
| Q37166753 | A 50-year journey to cure childhood acute lymphoblastic leukemia |
| Q58481753 | Acute lymphoblastic leukaemia |
| Q58481759 | Acute lymphoblastic leukemia |
| Q45071531 | An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001. |
| Q52877394 | Childhood acute lymphoblastic leukemia: 12 years of experience, using a Berlin-Frankfurt-Münster approach, in a Greek center. |
| Q38194444 | Chromatin modifiers and the promise of epigenetic therapy in acute leukemia |
| Q38904250 | Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders |
| Q54295812 | Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients. |
| Q49716164 | Clinical significance of monitoring ETV6-RUNX1 fusion gene expression in children with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation |
| Q46279150 | Copy number alterations determined by single nucleotide polymorphism array testing in the clinical laboratory are indicative of gene fusions in pediatric cancer patients |
| Q36528412 | Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing |
| Q47175107 | Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials |
| Q58774001 | ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol |
| Q36366644 | Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol |
| Q37359118 | Genomic characterization of childhood acute lymphoblastic leukemia |
| Q34500075 | Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study |
| Q34598903 | Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q38748648 | Leukaemia 'firsts' in cancer research and treatment |
| Q51026411 | Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor. |
| Q48125822 | Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry |
| Q48218289 | Molecular processes involved in B cell acute lymphoblastic leukaemia. |
| Q26749177 | New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia |
| Q33584136 | Outcome and Prognostic Factors for ETV6/RUNX1 Positive Pediatric Acute Lymphoblastic Leukemia Treated at a Single Institution in Korea |
| Q36163029 | Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? |
| Q35074246 | Pediatric donor cell leukemia after allogeneic hematopoietic stem cell transplantation in AML patient from related donor |
| Q39425967 | Pediatric haematopoiesis and related malignancies |
| Q55486808 | Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan. |
| Q33770150 | Prognostic factors and treatment of pediatric acute lymphoblastic leukemia |
| Q28087446 | Prognostification of ALL by Cytogenetics |
| Q98772371 | Quantitative monitoring of minimal residual disease in childhood acute lymphoblastic leukemia using TEL-AML1 fusion transcript as a marker |
| Q38367298 | RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia |
| Q28597831 | RUNX1 truncation resulting from a cryptic and novel t(6;21)(q25;q22) chromosome translocation in acute myeloid leukemia: A case report |
| Q33566597 | Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition |
| Q37292721 | Targeted Theranostic Approach for Glioma Using Dendrimer-Based Curcumin Nanoparticle |
| Q38017727 | Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies |
Search more.